Comparative Pharmacology
Head-to-head clinical analysis: ASBRON versus THEOPHYL 225.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASBRON versus THEOPHYL 225.
ASBRON vs THEOPHYL-225
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, and antagonizes adenosine receptors (A1, A2). This results in bronchodilation, reduced airway inflammation, and enhanced diaphragmatic contractility.
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
225 mg orally every 6 hours; adjust based on serum theophylline levels to maintain therapeutic range 10-20 mcg/mL.
None Documented
None Documented
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Terminal half-life: 3–12 hours (adults); shorter (1–5 hours) in children and smokers; prolonged in hepatic cirrhosis, heart failure, or elderly. Steady-state achieved in 1–2 days.
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Renal: 10% unchanged; hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination, with metabolites (e.g., 3-methylxanthine, 1,3-dimethyluric acid) excreted renally.
Category C
Category C
Bronchodilator
Bronchodilator